|
T1129 |
Benfotiamine
|
Benzoylthiamine monophosphate,S-Benzoylthiamine O-monophosphate |
Others
|
|
Benfotiamine (S-Benzoylthiamine O-monophosphate) is a synthetic S-acyl derivative of thiamine (vitamin B1), used as an antioxidant dietary supplement. |
|
T16910 |
Sorbinil
|
|
Reductase
|
|
Sorbinil is an Aldose reductase inhibitor. Sorbinil plays a therapeutic role in treating diabetes and diabetic complications decreases AR activity and inhibit the polyol pathway. |
|
T15756 |
Lidorestat
|
IDD-676 |
Reductase
|
|
Lidorestat (IDD-676) is an aldose reductase inhibitor (IC50: 5 nM) with effective, selective and oral activity. Lidorestat improves nerve conduction and reduces the formation of cataracts. Lidorestat can be used to treat... |
|
T34268 |
Raxofelast
|
IRFI016,IRFI-016,IRFI 016 |
|
|
Raxofelast (IRFI-016) is a hydrophilic, non-systemic, vitamin-like antioxidant that reduces ischemia-reperfusion injury in testis. Raxofelast is a good candidate compound for stopping oxidative stress after acute testicu... |
|
T0688 |
Ganciclovir
|
BW 759,RS-21592,2'-Nor-2'-deoxyguanosine |
Nucleoside Antimetabolite/Analog
,
Others
,
Antibiotic
,
Antifection
,
HSV
|
|
Ganciclovir (2'-Nor-2'-deoxyguanosine) is an ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegaloviru... |
|
T77523 |
ALR2-IN-1
|
|
Reductase
|
|
ALR2-IN-1 is a potent and selective ALR2 inhibitor with an IC50 value of 1.42 μM.ALR2-IN-1 possesses both antiglycemic and antioxidant activities and can be used to study the complications of diabetes. |
|
T10393 |
AT-007
|
|
Reductase
|
|
AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM). It reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats. |
|
T36619 |
Aligeron
|
|
Prostaglandin Receptor
|
|
Aligeron is a non-selective prostaglandin (PG) antagonist that inhibits PGF2α- and PGE2-induced decreases in blood pressure in cats, and can be used to inhibit PGF2α-induced diarrhea in mice and PGE2-induced paw edema in... |
|
T21327 |
Uridine triacetate
|
RG 2133 triacetate,PN-401,Tri-O-acetyluridine,PN401,RG 2133,RG-2133,PN 401,RG2133,RG2133 triacetate |
Others
|
|
Uridine triacetate (RG 2133 triacetate) (Tri-O-acetyl uridine), an orally active prodrug of uridine, is efficiently absorbed in the gut and swiftly deacetylated in the circulation to release free uridine. It is utilized ... |
|
T24808 |
SMI-6860766
|
TRAFSTOP 6860766,TRAF-STOP 6860766,SMI 6860766,TRAFSTOP6860766,SMI6860766 |
|
|
SMI-6860766 is a CD40-Traf6 interactions blocker that acts by ameliorating the complications of diet-induced obesity in mice. |
|
T68929 |
Lidorestat monohydrate
|
|
|
|
Lidorestat monohydrate is an aldose reductase inhibitor potentially for the treatment of diabetic neuropathy and diabetic complications. |
|
T70679 |
Spr 210
|
|
|
|
Spr 210 is an aldose reductase (AR) inhibitor with potential uses as a therapeutic agent for preventing and improving some diabetic complications. |
|
T27247 |
EGFR-IN-542
|
|
|
|
EGFR-IN-542 is a novel EGFR inhibitor. EGFR-IN-542 significantly reduces myocardial inflammation, fibrosis, apoptosis and dysfunction. It shows promise for use in the treatment of obesity-induced cardiac complications. |
|
T3977L |
Lifitegrast sodium
|
SAR-1118-023,SAR1118-023,SAR 1118-023,Xiidra |
|
|
Lifitegrast sodium (SAR-1118) is an LFA-1 antagonist for the therapy of vascular complications of the eye. It inhibits T cell-mediated inflammation by blocking the binding of two cell surface proteins (lymphocyte functio... |
|
T61706 |
α-Amylase/α-Glucosidase-IN-2
|
|
|
|
α-Amylase/α-Glucosidase-IN-2 (compound 5) exhibits strong inhibition activity towards both α-amylase and α-glucosidase enzymes, with IC 50 values of 13.02 μM and 13.09 μM, respectively. This compound shows promise for in... |
|
T38828 |
Mesdopetam
|
IRL790 |
|
|
Mesdopetam (IRL790) is a dopamine D3 receptor antagonist with a Ki of 90 nM and an IC50 of 9.8 μM for the human recombinant D3 receptor. It exhibits psychomotor stabilizing properties and is utilized in the study of moto... |
|
T73240 |
PDE5-IN-4
|
|
|
|
PDE5-IN-4, a phosphodiesterase 5 (PDE5) inhibitor, is utilized in research concerning acute myocardial infarction and reperfusion-related damage, gastrointestinal diseases, diabetic complications, and liver failure. |
|
T60897 |
Aldose reductase-IN-5
|
|
|
|
Aldose reductase-IN-5 is an inhibitor of aldose reductase (ALR2) that enhances the combination of inhibitory excitability and antioxidant capacity, thereby delaying the diabetes complications progress. |
|
T73305 |
ALR2-IN-3
|
|
|
|
ALR2-IN-2, a potent aldose reductase (ALR2) inhibitor, demonstrates IC50 values of 22 nM for rat ALR2 and 116 nM for ALR1, respectively. This compound is utilized in diabetic complications research. |
|
T28414 |
Piclozotan
|
SUN-N-4057,SUN4057,SUNN-4057,SUN-4057,SUNN4057 |
5-HT Receptor
|
|
Piclozotan (anhydrous), a 5-HT1A receptor agonist, demonstrated significant neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model, ameliorating motor complications in patients with advan... |
|
T73304 |
ALR2-IN-2
|
|
|
|
ALR2-IN-2, a potent aldose reductase (ALR2) inhibitor, exhibits IC50 values of 27 nM for rat ALR2 and 228 nM for ALR1, respectively. This compound is utilized in the research of diabetic complications. |
|
T60731 |
Mitobronitol
|
|
|
|
Mitobronitol (Myelobromol; DBM) is a brominated analog of mannitol. Mitobronitol is an anticancer agent classified as an alkylating agent. Mitobronitol shows myelosuppression effect that significantly reduced risk for se... |
|
T60640 |
SSAO inhibitor-2
|
|
|
|
SSAO inhibitor-2 (Compound 1) can be used in the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune... |
|
T60909 |
SSAO inhibitor-3
|
|
|
|
SSAO inhibitor-3 (Compound 2) can be used in the study of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune di... |
|
T72034 |
LI-2242
|
|
Others
|
|
LI-2242 is a potent inositol hexakisphosphate kinase (IP6K) inhibitor with IC50s of 31 nM, 42 nM, 8.7 nM, and 1944 nM for IP6K1, IP6K2, IP6K3, and IPMK, respectively.LI-2242 ameliorated hepatic steatosis by reducing the ... |
